NASDAQ:CCXI - Nasdaq - US16383L1061 - Common Stock - Currency: USD
Taking everything into account, CCXI scores 3 out of 10 in our fundamental rating. CCXI was compared to 555 industry peers in the Biotechnology industry. CCXI has a bad profitability rating. Also its financial health evaluation is rather negative. CCXI is valued quite expensively, but it does show have an excellent growth rating.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -31.74% | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | -353.17% | ||
PM (TTM) | -357.01% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.02 | ||
Debt/FCF | N/A | ||
Altman-Z | 9.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.54 | ||
Quick Ratio | 4.47 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | -26.68 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
51.99
+0.03 (+0.06%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 99.51 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 15.68 | ||
P/tB | 15.68 | ||
EV/EBITDA | -26.68 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -31.74% | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | -353.17% | ||
PM (TTM) | -357.01% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.02 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 134.75% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.54 | ||
Quick Ratio | 4.47 | ||
Altman-Z | 9.7 |